Home

Andrew A. F. Hack

CIK 1657434 · Chief Financial Officer · last filed 2026-01-06

Andrew A. F. Hack is a Chief Financial Officer who has filed 69 SEC Form 4 insider transactions across 7 companies since 2017. The most recent filing, for MRSN, was dated Jan 6, 2026. Across all open-market trades the lifetime net is −$258.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $27.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$27.79M

Companies

7

Total Filings

69

Lifetime Open-Market Net

-$258.51M

Filer Profile

Reported Address
300 THIRD STREET, FIRST FLOOR
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Mersana Therapeutics, Inc. (MRSN) Delisted Director 0 $29.08 $0 $48.36M 22 2026-01-06
Nuvalent, Inc. (NUVL) Delisted Director 1,449,766 $123.96 $179.71M -$156.54M 8 2024-12-13
DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Director 925,714 $15.50 $14.35M -$151.66M 15 2023-08-10
Allena Pharmaceuticals, Inc. (ALNA) Delisted Director — $0.07 — $0 3 2020-11-18
AVIR Director 5,365,659 $5.18 $27.79M $6.00M 2 2020-11-03
BCLS Acquisition Corp. (BLSA) Delisted Chief Financial Officer 487,500 $10.04 $4.89M $0 1 2020-10-26
EDIT Chief Financial Officer 0 $2.60 $0 -$4.67M 17 2019-02-06

Recent Filings

69 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-06 Mersana Therapeutics, Inc. (MRSN) Delisted Mixed −347,123 $0 EDGAR
2025-06-13 Mersana Therapeutics, Inc. (MRSN) Delisted Grant (A) — $0 EDGAR
2024-12-13 Nuvalent, Inc. (NUVL) Delisted Sell (S) −1,250,000 -$110.00M EDGAR
2024-06-14 Nuvalent, Inc. (NUVL) Delisted Grant (A) +2,499 $0 EDGAR
2024-06-12 Mersana Therapeutics, Inc. (MRSN) Delisted Grant (A) — $0 EDGAR
2024-03-29 Nuvalent, Inc. (NUVL) Delisted Sell (S) −880,000 -$64.04M EDGAR
2023-11-17 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Notice (144) −81,250 -$1.10M EDGAR
2023-08-10 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Sell (S) −1,500,000 -$21.59M EDGAR
2023-06-16 Nuvalent, Inc. (NUVL) Delisted Grant (A) — $0 EDGAR
2023-06-16 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Sell (S) −500,000 -$6.34M EDGAR
Showing 1–10 of 69
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.